Krystal Biotech, Inc. $KRYS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS4
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Pearl-2 NCT06724900 |
P1/2 | Active, not recruiting | Wrinkles in Decolletage; Pigmentation | 19 | 2025-07 |
| IOLITE NCT07016750 |
P3 | Recruiting | Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa | 16 | 2026-12 (+9 mo) |
| EMERALD-1 NCT06999733 |
P1/2 | Recruiting | Neurotrophic Keratitis | 60 | 2026-12 (+12 mo) |
| KYANITE-1 NCT06228326 |
P1/2 | Recruiting | Lung Cancer, Non-small Cell; Lung Cancer Metastatic | 250 | 2027-02 |
| KB707 NCT05970497 |
P1/2 | Recruiting | Cancer; Melanoma Stage III | 240 | 2027-07 (+12 mo) |